Marquette University

e-Publications@Marquette
School of Dentistry Faculty Research and
Publications

Dentistry, School of

9-25-2020

A Review on the Biodistribution, Pharmacokinetics and Toxicity of
Bismuth-Based Nanomaterials
Samireh Badrigilan
Fatemeh Heydarpanahi
Jalal Choupani
Mehdi Jaymand
Hadi Samadian

See next page for additional authors

Follow this and additional works at: https://epublications.marquette.edu/dentistry_fac
Part of the Dentistry Commons

Authors
Samireh Badrigilan, Fatemeh Heydarpanahi, Jalal Choupani, Mehdi Jaymand, Hadi Samadian, Mojtaba
Hoseini-Ghahfarokhi, Thomas J. Webster, and Lobat Tayebi

International Journal of Nanomedicine

Dovepress
open access to scientiﬁc and medical research

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 134.48.158.76 on 25-Aug-2021
For personal use only.

Open Access Full Text Article

REVIEW

A Review on the Biodistribution,
Pharmacokinetics and Toxicity of Bismuth-Based
Nanomaterials
This article was published in the following Dove Press journal:
International Journal of Nanomedicine

•

Samireh Badrigilan 1, *
Fatemeh Heydarpanahi 2, *
Jalal Choupani 3,4
Mehdi Jaymand 5
Hadi Samadian 5
Mojtaba HoseiniGhahfarokhi 1,5
Thomas J Webster 6
Lobat Tayebi 7

••
• •
•

1
Department of Radiology and Nuclear
Medicine, School of Paramedical Sciences,
Kermanshah University of Medical
Sciences, Kermanshah, Iran; 2Department
of Toxicology and Pharmacology, School
of Pharmacy, Mazandaran University of
Medical Sciences, Sari, Iran; 3Department
of Medical Genetics, School of Medicine,
Tabriz University of Medical Sciences,
Tabriz, Iran; 4Immunology Research
Center, Tabriz University of Medical
Sciences, Tabriz, Iran; 5Nano Drug
Delivery Research Center, Health
Technology Institute, Kermanshah
University of Medical Sciences,
Kermanshah, Iran; 6Department of
Chemical Engineering, Northeastern
University, Boston, MA 02115, USA;
7
Marquette University School of
Dentistry, Milwaukee, WI 53233, USA

*These authors contributed equally to
this work

Correspondence: Mojtaba HoseiniGhahfarokhi; Lobat Tayebi
Email m.hoseini@kums.ac.ir;
lobat.tayebi@marquette.edu
submit your manuscript | www.dovepress.com

DovePress

E

~

in a

http://doi.org/10.2147/IJN.S250001

Abstract: Here, bismuth-based nanomaterials (Bi-based NMs) are introduced as promising
theranostic agents to enhance image contrast as well as for the therapeutic gain for numerous
diseases. However, understanding the interaction of such novel developed nanoparticles
(NPs) within a biological environment is a requisite for the translation of any promising
agent from the lab bench to the clinic. This interaction delineates the fate of NPs after
circulation in the body. In an ideal setting, a nano-based therapeutic agent should be
eliminated via the renal clearance pathway, meanwhile it should have speciﬁc targeting to
a diseased organ to reach an effective dose and also to overcome off-targeting. Due to their
clearance pathway, biodistribution patterns and pharmacokinetics (PK), Bi-based NMs have
been found to play a determinative role to pass clinical approval and they have been
investigated extensively in vivo to date. In this review, we expansively discuss the possible
toxicity induced by Bi-based NMs on cells or organs, as well as biodistribution proﬁles, PK
and the clearance pathways in animal models. A low cytotoxicity of Bi-based NMs has been
found in vitro and in vivo, and along with their long-term biodistribution and proper renal
clearance in animal models, the translation of Bi-based NMs to the clinic as a useful novel
theranostic agent is promising to improve numerous medical applications.
Keywords: bismuth nanoparticles, biocompatibility, pharmacokinetic, biodistribution and
clearance

Introduction
Bismuth-based nanomaterials (Bi-based NMs) hold great potential as theranostic
agents due to their high atomic number (Z= 83), X-ray sensitive capabilities,
near-infrared driven semiconductor properties, and low cost. These characteristics have been used to develop theranostic platforms for tumors and vascular
computed tomography (CT)1,2 as well as photoacoustic (PA)3,4 imaging
approaches, drug delivery,5,6 radiation therapy (RT),7,8 photothermal (PTT)6,9
and photodynamic (PDT)10,11 therapeutic modalities.12 All administrated exogenous materials, as diagnostic or therapeutic agents, should be entirely cleared
from the body within a satisfactory time after injection, according to the
requirements as reported by the US Food and Drug Administration (FDA).13
Despite effective contrast signal enhancement and tumor inhibition triggered by
Bi-based NMs, their biocompatibility and easy excretion from the body
are major characteristics that minimize the possible risks associated with the
interactions of Bi-based NMs within biological systems.
International Journal of Nanomedicine 2020:15 7079–7096
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Once injected, NPs are transferred by the bloodstream
to target tissues and different organs. In the meantime,
immunological mechanisms start a cohort of processes to
eliminate these foreign particles from the body.14
Therefore, highly active clearance mechanisms affect the
expected distribution of Bi-based NMs in different organs.
The travelling pattern of Bi-based NMs in different organs
or tissues is determined by their physicochemical properties, principally considered as the biodistribution and the
rate of NP recognition and elimination via metabolism, the
immune system and excretion referred to as pharmacokinetics (PK).15
Biodistribution and PK are key points to maximize the
expected therapeutic functionality of Bi-based NMs and to
minimize side effects in any clinical or diagnostic
application.
Besides, the toxicity of Bi-based NMs on living organisms is an important factor that limits their biomedical
applications. Bi-based NM induced-toxicity depends on
their concentration, duration of interaction with living
matter, biological stability, and their accumulated dose in
tissues and organs.16 For future clinical translation, understanding the underlying biodistribution and clearance
mechanisms of Bi-based NMs is a primary step.
For the ﬁrst time, this review paper provides a narrative
view on the in vivo biological barriers encountered by Bibased NMs. The parameters that play key roles in the
clearance pathways, body distribution and ultimate fate
of Bi-based NMs are discussed to design agents based on
Bi-based NMs of high biosafety and signiﬁcant diagnostic
and therapeutic efﬁcacy for future biomedical applications.

Toxicity
Free types of heavy metal elements are very toxic, thus,
their bio-elimination from the body is an important issue
that should be carefully considered in their design for
medical applications. Bi has been introduced as the only
heavy metal that is almost non-toxic.17 Bi compounds are
generally considered as safe heavy metals compared to its
neighboring elements, such as mercury (Hg), thallium (Tl),
and lead (Pb). Also, unlike other heavy metals like gold
and platinum, Bi is not stable in the body and is anticipated to slowly decompose into soluble Bi (III)18 thus,
their fast excretion from the body is a challenge for their
use in clinical applications. Dissolved Bi (III) ions from
BiNPs are cleared via a cysteine-rich protein in kidneys
(called metallothionine) and are excreted by the urine. It
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has been shown that Bi reacts with this protein earlier than
other elements, regardless of pH.
Bi (III) compounds have been used for many centuries
in the medical ﬁeld, so it is thought that their ions are also
safe in biological conditions.19 A concentration of 50 µg
Bi (III)•mL−1 has generally been considered as
a maximum biocompatible plasma concentration. For
more than three centuries, different compounds of Bi
(III) (such as colloidal bismuth subcitrate (CBS, De-Nol),
bismuth subcitrate potassium (Pylera), bismuth subsalicylate (Helidac) and ranitidine bismuth citrate (RBC,
Pylorid, Tritec)) have clinically been used for some gastrointestinal disorders, of which a daily dose can even
increase to several grams.20,21 Also, Bi can eradicate
Helicobacter pylori in peptic ulcers, syphilis, and tumors
and reduce renal toxicity caused by cisplatin.22 For
patients suffering from various stomach diseases, a high
dose of up to ~ 4.2 g of bismuth subsalicylate is frequently
prescribed, demonstrating the in vivo biosafety of bismuth
below acceptable levels of toxicity.

In vitro Toxicity
Cell Viability
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is a convenient colorimetric
approach for measuring cellular metabolic activity, which
can be used as a sensitive indicator of cell viability and
proliferation. Based on published evidence, the cytotoxicity of Bi-based NPs (such as bismuth selenide (Bi2Se3),
bismuth sulﬁde (Bi2S3), copper bismuth sulphide (Cu3
BiS3), and pure Bi NPs) is insigniﬁcant against various
cell lines even at high concentrations.3,5,6,18,23-35 In the
case of Bi2S3, Liu et al36 have evaluated the cytotoxicity
of Bi2S3 NPs in a panel of different cell lines, including
lung adenocarcinoma A549 cells, human embryonic kidney 293 cells (HEK293), umbilical vein endothelial cells
(HUVEC), and hepatocarcinoma (HepG2) cells. They
found that Bi NPs induced minimal toxicity in HepG2
and HUVEC cells, representing negligible cytotoxicity on
the human liver and blood vessels. The viability of A549
cells was 78% at the highest concentration of 160µg/mL,
which indicated trivial cytotoxicity on lung cells. In contrast, HEK293 cells showed a dose-dependent vulnerability to Bi2S3 NPs. A concentration of 20 and 160µg/mL of
Bi2S3 NPs decreased the viability of HEK293 cells down
to 80% and 50% of controls, respectively. Therefore, kidney cells showed the most vulnerability to Bi2S3 NPinduced cytotoxicity which was related to the release of
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Bi ions. The team also showed that Bi2S3 NP-treatment
prompted the expression of microtubule-associated protein
light chain 3 (LC3) in HEK293 cells, which highlighted
autophagy-dependent mechanisms of Bi2S3 NPs cytotoxicity. Rabin et al37 have also reported a median lethal dose
(LD50) for U937 cells in the presence of 8 mM free Bi
ions, while a LD50 value was achieved at a concentration
of 100 mM Bi in PVP- Bi2S3 NPs (BPNPs). For HepG2
hepatocarcinoma cells, the LD50 value of Bi3+ ions and
BPNPs was 5 mM and 114 mM, respectively. It is desirable that the LD50 value of the NPs be higher than the
required dose (ED) for their respective applications. The
ED/LD50 proﬁle for U937 cells treated with BPNPs was
similar to that observed for an iodinated agent, while
a superior proﬁle was found for HepG2 cells.37
Besides, Bi-based NMs can directly cause oxidative
stress injury by disruption on mitochondrial and lysosomal function. Mahmoud et al38 used kidney (NRK-52E),
liver (HepG2), lung (A549) and intestine (Caco-2) cell
lines to evaluate the cytotoxicity of Bi2O3 NPs and found
that the half-maximal inhibitory concentration (IC50) was
96.55, 35.11, 59.08, and 93.55μg•mL−1, respectively.
They found that the level of malondialdehyde (MDA)
and 8-hydroxydeoxyguanine (8-OHdG) increased while
glutathione (GSH) levels decreased due to Bi2O3-induced
cytotoxicity, proving disrupted function of mitochondria
and lysosomes. Furthermore, the cell vulnerability to
genotoxic damage induced by Bi2O3 NPs was ranked as
NRK-52E > Caco-2 > HepG2 > A549. For two other
types of Bi-based NMs,39,40 it been shown that
a concentration of 100 μg Bi.mL−1 can induce cytotoxicity in half of human skin-derived (HaCaT) cells by
provoking oxidative stress mechanisms, disturbing the
cell cycle, and induction of apoptosis. In contrast, several
reports found no evidence regarding the cytotoxicity of
Bi-based NPs even at high doses. A high dose of 3 mg Bi
·mL−1 in Bi2S341 and bismuth ferrite (BFO)10 NPs
achieved a viability over 80% against HeLa and HepG2
cells, respectively. Furthermore, doses of 100 mg mL−1
and 0.932 mg•mL−1 of Bi2O3 NPs induced no cytotoxicity in murine periodontal ligament and rat osteosarcoma
cells and monkey kidney cells, respectively.42,43
The maximum safe doses of Bi-based NMs after 24h of
incubation are listed in Table 1. As shown, no cytotoxicity
effect was observed for both normal and tumoral cells after
24h of incubation with doses of 400 to 15,000 μg•mL−1 of
all these Bi-based NMs.
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Hemolytic Effect
For in vivo biomedical applications of NPs, bloodcompatibility is a critical test that should be investigated
to determine the hemolytic capability of NPs when
exposed to blood components. As a result, nanoprobes
with a high degree of hemolysis are not suitable for introduction into the physiological environment. According to
the ASTM E2524-08 standard, red blood cell (RBC)
damage from foreign agents introduced into the body are
signiﬁcant when the degree of hemolysis reaches 5%. The
results reported for Bi-based NMs revealed excellent
blood compatibility with a hemolysis effect lower than
2%,1,2,4,6,34,35,46,47,54,58,66 even at a high concentration of
800 µg•mL−1.3

In Ovo Toxicity
The toxicity of Bi2O3/HSA core-shell NPs was tested on
fertilized eggs of the Gallus chicken. Aviv et al poked
a small hole in an egg air sac and injected the solutions
directly over the permeable air sac membrane with
a hypodermic syringe in the third day of embryonic development. After 14 days, the number of alive chicken
embryos in the groups injected with Bi2O3 NPs with and
without a human serum albumin (HAS) shell were similar
to that of the untreated group, indicating high biocompatibility of Bi NPs. Also, the doxorubicin injected embryos
was considered as a positive group.71

In vivo Toxicity
In vivo Toxicity in Caenorhabditis Elegans
Caenorhabditis elegans (C. Elegans) is a well-known
model organism that has been commonly used in the
ﬁeld of biology. As a small, free-living, nematode worm,
it is one of the simplest organisms with a neural structure,
which includes a battery of sense organs. It is
a multicellular eukaryote with simple digestive, reproductive and nervous systems, which in its simplicity makes it
a great model for a detailed study in cell differentiation,
development, neurology and genetics. Interestingly, its
transparency facilitates the study of cell differentiation
simultaneously allowing optical imaging of its structure.
These characteristics make it an outstanding model for
evaluating nanomaterial toxicity.
The bright ﬁeld images show the uptake of Bi2S3
@SiO2 NRs by C. Elegans.72 When following 18 days
after co-cultivation of C. Elegans with different doses of
Bi2S3@SiO2 NRs, no observable proliferation inhibition
was found in the C. Elegans. Additionally, no noticeable
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Table 1 The Maximum Safe Doses of Bismuth-Based Nanomaterials After 24h of Incubation
Nanomaterials

Cell Lines

Dose

References

Nanomaterials

Cell Lines

(µg• mL−1)
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Cu3BiS3

29

HeLa

200

44

MCF-7
HUVEC*

100

45

Bi

BEL-7402

HeLa

500

18

U937

10,000

37

HepG2
MCF-7

400

46

200

47

U14
4T1

500
400

1

L02*
4T1

160

50

HeLa

500

34

MCF-7
HeLa

600

23

HeLa

300

4

HUVEC*
4T1

100

53

HeLa

400

30

4T1
4T1

300
160

24

SMMC-7721
200

31

HeLa
MCF-7

600
150

5

HeLa

200

49

HeLa

References

(µg• mL−1)

200

4T1

Dose

VSMC
4T1

L929*

HUVEC*
48

32

NIH-3T3
HUVEC
Bi2Se3

4T1

200

26

3T3*
MCF-7

200

51

HeLa

400

3

HUVEC*
H22

200

52

100

7

HeLa
HeLa

200
200

8

BJ5ta*
HepG2

100

27

HeLa
HUVEC*

300

2

HeLa

500

34

4T1

15,000

55

MCF-7
HepG2

3000

10

J774
HeLa

7500

41

100

56

40

6

PC3

200

25

MCF-7

200

57

L929

500

59

BEL-7402

BiFe

Bi2S3/Au

4T1
MCF-7

Bi2S3

54

Bi2S3/G

HUVEC*
HeLa

28

MCF-7
HepG2
BEL-7402
FeSe2/Bi2S3

4T1

200

9

BiSe/G

HeLa

150

33

GdBi

C6

200

58

800

11

Bi2O3:Yb3+/Er3+

HeLa

1000

60

400

61

Bi2S3/FeS2

4T1

800

62

500

35

BiOI

HeLa

4200

63

200

64

4T1

200

65

BiOCl

COS-7*
Bi2WO6

HeLa
HUVE
HeLa

GBi

HeLa
MCF-7

BMS

HUVE
HeLa

HeLa

(Continued)
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Table 1 (Continued).
Nanomaterials

Cell Lines

Dose

References

Nanomaterials

Cell Lines
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(µg• mL−1)

References

Dose
(µg• mL−1)

K0.3Bi0.7F2.4

HeLa

500

66

(BiO)2CO3

Huh-7

5mM

48

BiOBr

L929

1000

67

Bi2S3-MnO2

U14

10

68

AgBiS2

UMR-106

500

69

BPZP

4T1

100

70

Note: * The cells are non-cancer cells.
Abbreviations: 3T3, mouse embryonic ﬁbroblast; 4T1, breast cancer cell; AgBiS2 NPs, silver bismuth sulﬁde; BEL-7402, liver carcinoma cell; BJ5ta, human fore skin
ﬁbroblast; Bi, pure bismuth; Bi2S3, bismuth sulﬁde; Bi2Se3, bismuth selenide; Bi2S3/Au, bismuth sulﬁde-gold; Bi2S3/G, bismuth sulﬁde-graphene; Bi2S3-MnO2 NPs, bismuth
sulﬁde and manganese oxide nanocomposites; Bi2WO6, bismuth tungstate; BiFe, bismuth ferrite; (BiO)2CO3, bismuth subcarbonate; BiOBr, bismuth oxybromide; BiOCl,
bismuth oxychloride; BiOI, bismuth oxyiodide; BMS NRs, bismuth sulﬁde -mesoporous silica; BPZP, bismuth sulﬁde-linked zinc protoporphyrin; BiSe/G, bismuth selenidegraphene; C6, glioma cell; COS-7, monkey kidney ﬁbroblasts; Cu3BiS3, copper bismuth sulﬁde; FeSe2/Bi2S3, iron diselenide-bismuth selenide; GBi, graphene-bismuth; GdBi,
gadolinium-bismuth; H22, hepatic carcinoma cell; HeLa, cervical cancer cell; HepG2, hepatic carcinoma cell; Huh-7, human liver cell; HUVEC, human umbilical vein
endothelial cell; J774, Mus muscles reticulum cell sarcoma; L02, human hepatic cell; L929, murine ﬁbroblast cell; MCF-7, breast cancer cell; PC3, human prostate carcinoma;
SMMC-7721, hepatic carcinoma cell; U14, cervical carcinoma cell; U937, macrophage cells; VSMC, vascular smooth muscle cell.

effect on their worm body length in comparison to the
group with any treatment was induced, therefore there was
not any toxicity mediated by Bi2S3@SiO2 NRs for the
C. Elegans. After three days, the auto-ﬂuorescence intensity in the worm intestine in the control group was similar
as those exposed to different concentrations of Bi2S3
@SiO2 NRs, which could be attributed to the negligible
effect of NRs on the lipofuscin level.

In vivo Toxicity in Zebraﬁsh
The zebraﬁsh (Danio rerio) is a commonly used animal
model in a variety of biological sciences due to its unique
features, such as well characterized embryonic stages,
a completely sequenced genome with high similarity to
the human genome, high rate of fecundity and rapid development and affordable husbandry. Also, they have similar
features and mechanisms of behavior to mammalian models in toxicology, which make them a suitable model for
toxicity testing.
After treatment with bismuth−asparagine coordination
polymer spheres (BACP-2),73 a signiﬁcant deformation
was observed in zebraﬁsh morphology including shortened
body length and head diameter (particularly eyes), but it
was highest at 28 postfertilization (hpf). In addition, at 52
and 72 hpf, an observable pericardial edema was found
compared with the un-injected embryos (Figure 1A).
However, a recovery of the BACP-2 mediated effects
was found by embryos at 100 hpf. Also, alcian blue staining revealed that the BACP-2 had no effect on cartilage
development (Figure 1B).
Cellular movement and cell fate determination are two
vital processes for the normal formation of organs. The
expression of krox20 (Egr2) has no signiﬁcant difference

International Journal of Nanomedicine 2020:15

in rhombomeres (r) 3 and 5 between the two groups.
However, due to the narrower space between r3 and r5
in all of the injected embryos, it is evident that the BACP2 injection leads to a decrease in the size of the hindbrain.
The different expression levels of otx2—as a marker in the
development process of the forebrain, midbrain and eyes
—induced the abnormal small-eye phenotype in the
embryos. Analysis of cardiac myosin light chain 2
(cmlc2) expression as a heart-speciﬁc marker revealed
that BACP-2 caused defects in heart development in zebraﬁsh embryos. Also, the abnormal cell migration and
slow growth of the treated embryos resulted from the
dysregulation in the expression of not tail (ntl). Overall,
these results indicated that BACP-2 impaired normal
embryonic head and heart development in zebraﬁsh
(Figure 1C).

In vivo Toxicity in Murine Models
The rats and mice, known as murine models, are commonly used to investigate the in vivo toxicity induced by
NPs. The histological analysis, physical and behavioral
signs, hematological parameters and blood biochemistry
analysis, and immunotoxicity are considered as major
factors for toxicity assessment in the case of such mammalian models. In this subsection, toxicity index factors
and related studies will be described in detail.
Physical and Behavioral Signs
Bodyweight, litter size, and behavior traits such as eating,
drinking, and mating, all can be monitored to measure the
in vivo toxicity proﬁle of a NP, and deviation from the control
case usual reﬂects a physiology disorder. In the case of Bi NPs,
the impact of toxicity on the physical function of the body has

submit your manuscript | www.dovepress.com
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Figure 1 (A) Morphological features of embryos injected with different concentrations of bismuth−asparagine coordination polymer spheres (BACP-2) at different times
post-fertilization. (B) Alcian blue staining of BACP-2 effect on cartilage growth at 5 hours postfertilization (hpf) (a-j: lateral view; a’-l’: ventral view).(C) . Expression of
krox20 (at 12 hpf), orthodenticle homeobox 2 (otx2) (at 12 hpf) and cardiac myosin light chain-2 (cmlc2) (at 24 hpf) genes in uninjected embryos and embryos after injection
with 400 pg of BACP-2. Reprinted with permission from He N, Li X, Feng D, et al. Exploring the toxicity of a bismuth–asparagine coordination polymer on the early
development of zebraﬁsh embryos. Chem Res Toxicol. 2013;26(1):89–95.73 Copyright 2013 American Chemical Society.

only been physically evaluated by monitoring changes in the
bodyweight of treated animals (rats or mice). The weight losttriggered by various types of Bi NPs has been investigated with
no important changes in comparison to controls. Speciﬁcally,
as a model, a 90 day follow-up of the intraperitoneally injection
of Bi2Se3 NPs (20 mg/kg) into C57 male mice8 revealed that
polyvinylpyrrolidone coated bismuth selenide nanoparticles
(PVP-Bi2Se3 NPs) were not able to induce any signiﬁcant
harmful effects on mice growth, and there was no statistically
meaningful difference in mice body weight in comparison to
the control mice. In addition, it has been reported that no
obvious abnormal behavior was observed after treatment,
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indicating physically and behaviorally excellent in vivo compatibility of PVP-Bi2Se3 NPs.
Histology
For histopathological analysis, major organs (typically the
liver, lung, spleen, heart, and kidney) are harvested from
the animal models exposed to the nanoprobes, placed in
a formalin solution, embedded in parafﬁn, sectioned into
tiny slices, stained with hematoxylin and eosin (H&E) and,
ﬁnally, an optical microscope was employed to observe
possible cell damages, including tissue death, lesions, and
inﬂammation.

International Journal of Nanomedicine 2020:15

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 134.48.158.76 on 25-Aug-2021
For personal use only.

Dovepress

In all histological in vivo toxicity assessments of Bi
NPs with various shapes, coatings and compounds, the
major organs (heart, liver, spleen, lung, and kidney) from
the experimental animals showed no/low tissue damage
and maintained normal physiological properties. All histological results indicated general innocuity of Bi to induce
abnormal histological changes in the organs. After treatment with the PVP-Bi2Se3 NPs,8 no increase in the
immune response was found in the thymus of mice during
the 90 day experiment; in contrast, the spleen index grew
steadily during the ﬁrst 30 days, then declined with time.
No damage signs and pathological lesions were found in
the spleen and kidney organs during the course of treatment, but a slight pathological change after injection of the
PVP- Bi2Se3 NPs was observed in the liver. A 90 days
follow-up study revealed a recovery mechanism within the
damaged organs to the normal state. The other organs
(such as the heart, lung, testis, bladder, and brain) revealed
no toxicity index signs during the 90 days. A high aggregation degree of the PVP-Bi2Se3 NPs as dark spots with
a size smaller than 1 µm was observed in spleen optical
images on days 1 and 7, but they disappeared after 90
days.
Hematology and Blood Biochemistry
In the complete blood panel analysis, very important
hematology markers including RBC, white blood
(WBC) and platelet (PLT) counts, hemoglobin (HGB)
concentration, mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH) concentration, mean corpuscular hemoglobin concentration (MCHC), and hematocrit (HCT) are monitored to investigate the overall
physiological health after administration of NPs into the
body. Blood biochemistry analysis was employed to
investigate the liver and kidney function by measuring
markers corresponding to the liver (such as alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) activities) and the kidneys (such
as serum levels of albumin (ALB), blood urea nitrogen
(BUN), creatinine (CREA) and globulin (GLOB)).
The measurement of typical hematological parameters,
such as WBC and RBC counts, did not indicate any signiﬁcant differences in PVP-Bi2Se3 NP-treated mice, compared with the untreated group. However, the increased
PLT count returned to the normal level after 90 days of
treatment.8 These results demonstrated that PVP-Bi2Se3
NPs have low toxicity in mice. Blood chemistry parameters in the injected group had no signs of a direct effect.
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The injected NPs had infraction with important proteins in
serum, such as albumin, ﬁbrinogen, and insulin. After
1-day of treatment with the PVP-Bi2Se3 NPs, no observable differences were measured in all parameters compared
to the control group. Meanwhile, a large fraction of the
PVP-Bi2Se3 NPs accumulated in the liver site during the
ﬁrst day but did not induce serious damage at this time
point. On day 7, compared to that of day 1, the change of
ALT content was signiﬁcant for the NP-treated mice,
unlike AST and CREA. The ALT level reached a normal
state after 90 days of treatment, which could be due to the
slight hepatic damage induced by the Bi2Se3 NPs during
the ﬁrst 7 days and the damage recovery with more time.
Hematological and blood biochemical analyses of the Bi2
Se3 NP8 injected mice showed no obvious irregularities in
hematological and organs physiological functions. The
in vivo coagulation studies showed that the Bi NPs cannot
induce any signiﬁcant change in the levels of ﬁbrinogen
(FIB), prothrombin time (PT), thrombin time (TT) or
activated partial thromboplastin time (APTT) within
blood plasma in comparison to the control plasma.
The reported results showed normal metabolism in all
of the major organs of the experimental animals, and there
was no signiﬁcant abnormal body function after exposure
to the Bi NPs. The same results have been reported for the
in vivo safety of Bi-based NMs in previous
studies.3,4,29,61,62,74,75

Clearance Pathways
Elimination of undesirable materials from the body,
namely excretion or clearance, plays a critical role in
biological processes, which potentially helps to prevent
damage and toxicity. Clearance of agents through the
renal (urine) and hepatic (bile to feces) pathways are
considered as two major excretion routes.76
Renal clearable agents are a better choice, as they
are able to be quickly removed from the body; therefore,
slight cellular internalization and metabolism will occur.
So, it is a common method to reduce exposure of the
body to such agents. The shape, surface charge, and size
of materials are major factors for the excretion of these
agents through the urinary system based on glomerular
ﬁltration in the kidneys.76 The typical ﬁltration-size
threshold (FST) of capillary walls of the glomerulus is
about 6 nm, indicating that the ﬁltration of materials
with hydrodynamic diameters (HDs) larger than the FST
is not possible by the kidneys. When a non-renal clearable substance is introduced into the body, they remain
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in the blood circulation and are swallowed by phagocytosis cells such as kupffer cells. These cells are resident
macrophages in the reticuloendothelial system (RES)
that identify and phagocytose foreign antigens and matters (>10 nm) in the blood to remove them from the
body. RES, as a part of immune system, are found
throughout the body, mainly in the spleen, liver and
other reticular connective tissues, where the exogenous
materials are metabolized and removed by the hepatic
pathway. In hepatic excretion, the liver is responsible
for metabolism and biliary excretion and ﬁnally, the
foreign materials are excreted in feces. The hepatic
route with a complex pathway and longer retention
time than the renal route increases the risk of health;
therefore, renally excreted probes are better to choose
for clinical applications.

Biodistribution Proﬁle and Clearance
Pathway of Nanoprobes
In an in vivo system, molecular agents with different
structures, properties, and functions behave similarly
showing a non-speciﬁc distribution, short distribution
time, short residence time in blood circulation and almost
complete renal clearance within a short-time.76 The
probes, based on a small molecule with a smaller size
than FST, do not experience any interactions with serum
proteins in the blood; they remain intact and enter into
urine after ﬁltration by the glomerular capillary walls
(Figure 2A). Hepatic clearance is another elimination
route of exogenous agents from the body, which acts
almost as a dominant excretion route in the case of nanoprobes and some of the molecular probes with the binding
of serum proteins. While the molecular probes can be
almost completely excreted via the renal and/or hepatobiliary pathway during a nearly short period of several
hours or few days, nanoprobes ﬂow out of the blood
circulation and signiﬁcantly accumulate in organs with
reticular and endothelial characteristics for a long time
(Figure 2B).
In a physiological medium, the HDs of the most developed Bi NPs are larger than what can pass through the
capillary walls and enter urine (~ 6–8 nm). Their large HDs
can be attributed to two major reasons. First, their actual size
is larger than FST, here's a list, spherical Bi NPs (74 nm),18
Cu3BiS3 hollow nanospheres (80 nm),5 bismuth sulﬁde
nanorods (diameter of 10 nm and length of 50 nm),24 bismuth selenide spherical-sponge NPs (125 nm),3 FeSe2- Bi2
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Se3 nanosheets (thickness of ≈2.6 nm and average diameter
of ≈100),9 rGO/Bi2S3 nanocomposites (average diameter of
~100 nm and thickness of ~1.2 nm),6 and Yb3+/Er3+-codoped
Bi2O3 nanospheres (350 nm).60 Second, the size of the
nanoprobes becomes dramatically larger in a biological
environment (even some with a core size smaller than 6
nm), because their surface coating and adsorption of serum
proteins increase—for example, the core size of Bi2S3 NPs is
6.1 nm, but the HD of BSA-stabilized Bi2S3 NPs increases to
39.52 nm.28 The HD of BiOI NPs with a core size of 2.6 is
~16 nm.63 A polyvinylpyrrolidone (PVP) coating increased
the size of Bi nanodots form 2.7 nm to 11 nm.1
The liver and spleen are predominately the organs that
accumulate very large Bi nanoprobes (HD > 400 nm), with
> 90% of the injected dose (% ID), and a low concentration of Bi is excreted by the urine (~ 5%ID). The kidney
uptake of Bi NPs with a size close to the FST (~ 10 nm) is
still signiﬁcantly lower than those measured for the liver
and spleen.1,77 It was found that the size of the nanoprobes
acts as a dominant factor in the ﬁltration efﬁciency and
elimination via the hepatic route. The type of coating is
considered as another factor in hepatic clearance.
To date, Bi NPs have been widely coated by a polymer
such as PVP, dextran, bovine serum albumin (BSA),
human serum albumin (HSA), Tween or polyethylene
glycol (PEG).3,4,11,27,29,55,56,78 The variety of serum proteins present in the blood reaches 300 different types,
which forms a diverse protein corona and interacts with
the high energy surface of the particle. The increase in the
HDs and macrophage uptake by RES organs mainly is due
to the type, bioactivity, and concentration of serum protein
adsorption to NPs.79,80 The PEG polymer, as the surface
coating, is commonly used to prolong blood retention time
and reduce uptake by RES organs of Bi NPs; in contrast,
the large HDs of the generated NPs do not allow for renal
clearance, maybe with ﬁne control of the PEG density on
the Bi NPs surface, the PEGylated-Bi NPs can be cleared
via the urinary system. The PEG polymer with a molecular
weight of about 500–2000 canform a coiled conformation
resistance to protein binding.
Almost all of the developed Bi NPs follow a non-renal
clearance proﬁle and demonstrate liver homing ability in
the range of 8 ~ 70% ID•g−1 at 1 ~ 24 h p.i. with any
shape, hydrodynamic size (larger than FST), surface coating, and chemical composition, while the reported dose in
the liver and spleen for molecular probes was ~ 0.1–1.0 %
ID•g−1,76 (~ 10–1000 times smaller). The reduction of NP
core size and also the development of a protein-adsorption
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-resistant coating on the NP surface mainly help to achieve
higher urinary clearance efﬁciency of Bi NPs. But this
strategy is not always feasible, since NPs exhibit sizedependent properties and size reduction may compromise
the desired properties and even could vanish following the
reduction of particle sizes to less than ~ 5 nm. Also, the
synthesis of ultrasound microcapsules/NPs with a size of
less than 5 nm is impossible. To maintain NP optical
properties for cancer imaging and therapy, accelerating
the elimination of NPs of a large size from the body and
the development of larger degraded nanoprobes is an alternative. To date, a few degradable NPs based on Bi have
been reported. The Bi-based nano compounds are mainly
in the form of Bi/Fe, Bi2Se3, Bi2S3 and Cu3BiS3, and the
biodegradation mechanisms of each type are fully
described in the following section.
In the case of Fe/Bi NPs,27 the concentration of Bi in the
kidney clearly was higher than that measured for Fe 2
h after injection of the Bi–Fe3O4 nanocomposites (BION),
while their content in the other major organs was almost
similar. This shows that the Bi element could be cleared
efﬁciently through the urinary route, due to the degradation
of BION in the acidic environment. Such higher levels of Bi

International Journal of Nanomedicine 2020:15

in the kidneys and urine, compared with Fe, could be
attributed to the conﬁscation of released Fe ions by ferritin
for the synthesis of hemoglobin, whereas there is no such
system for the consumption of released Bi ions in the body,
allowing for the kidney ﬁltration of free Bi ions. In contrast,
after the ﬁrst incubation of the BION in a 10% FBS solution
for 1 h, a reduction in the size from 98 to 90 nm was
observed; as time passed to 24 h, the size of BION surprisingly was found to be 48 nm, supporting the supposition of
BION degradation. Also, the release test indicated that the
amount of Bi and Fe after 4 h in the lysosomal- and bloodmimicking ﬂuid was 80% and 19%, respectively.
In the case of Bi2Se3 NPs,8 the Bi2Se3 nanoprobes can
be degraded and release Bi and Se ions into the biological
environment, providing for renal excretion. The liver,
spleen, and kidneys are predominately the homing sites
for nanoplates (lateral size of 53.8 nm and thickness size
of 4 nm, HD= 59.8 nm), followed by the bladder and
testes. The Bi2Se3 nanoplates undergo a fast oxidation
process in the bloodstream. As a result, the oxidized and
intact nanoplates are absorbed by organs containing phagocytic cells, and in contrast, the released Se ions remain
in blood circulation for a long time and are excreted via
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the urinary system. The Bi- accumulated level in all organs
decreased as time increased to 90 days, indicating timedependent clearance effects. Interestingly, the downward
trend of the amount of Se continued for 30 days, whereas
the signiﬁcant level of Se in the kidneys, testes, and
bladder was visible 90 days after administration.
In another sample, the renal excretion was the main
excretion mechanism on the ﬁrst day for Bi in the Bi2Se3
NPs modiﬁed by selenocysteine and polyvinylpyrroliNPs),7
while
such
done
(PVP
Bi2Se3@Sec
a mechanism did not exist for Se ions, indicating efﬁcient renal clearance of Bi. It should be noted that the
liver, as a major site to synthesize selenoenzymes and
selenoproteins, converts Se derivatives to selenoproteins
via reduction and methylation reactions. Doran suggested the methylation mechanism of selenium as follows: in the methylation process of SeO23 , Se0 could be
considered as a starting substrate or the intermediate
product of methylation; selenite (IV), as a precursor of
selenium integrated into selenoproteins, forms hydrogen
selenide (H2Se) through reduction and methylation
mechanisms. Therefore, it is not surprising that released
Se ions from Bi2Se3@Sec NPs signiﬁcantly accumulated
in the liver.
In the case of Cu3BiS3 NPs:48 The kidneys are the
major organ contributing to the metabolism of TweenCu3BiS3 nanodots (core size of 10 nm, HD ~ 22 nm),
and the liver and spleen are next. The Cu3BiS3 NDs

were fully degraded and metabolized and were excreted
from the whole body within a relatively short time. The
content of nanodots in the kidneys increased to 35%
ID•g−1 in the ﬁrst 2 h, reached a maximum (45% ID•g−1)
at 6 h post-injection, and then decreased to 22% ID•g−1 at
24h. In contrast, the ND level was as high as 25% ID•g−1
and 34% ID•g−1 in the liver, 6% ID•g−1 and 23% ID•g−1 in
the spleen after 2 and 6 h, respectively, while in the rest of
the organs (heart, lungs, stomach, and intestine), lower
than 4% ID•g−1 was found. After 1 day, it decreased to
7% ID•g−1 in the liver and 11% ID•g−1 in the spleen. The
in vivo distribution and clearance behaviors of Cu3BiS3
NDs were consistent with the acquired CT images at
different times (Figure 3A). During 10 min, the contrast
of the liver and kidneys was remarkably enhanced, indicating the quick elimination of Cu3BiS3 NDs via the
urinary system. As time increased to 6 h, the liver had
the strongest signal and the spleen was visible, while the
bladder was ﬁlled with Cu3BiS3 NDs. Up to 2 h after
injection, the nanoprobes were almost exclusively
removed via fecal excretion, as renal clearance gradually
took over as the dominate clearance system, so that the
efﬁciency of renal excretion was almost 2-times and
3-times higher than fecal excretion 6 h and 24 h after
injection, respectively (Figure 3B).
In biological conditions, the nonstable Cu+ ions easily
undergo an oxidation process and react with ligands like
Cl−, S2- thiols, peptides, and proteins. The degradation and
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Figure 3 (A) Computed tomography (CT) images of mice before and after injection of Cu3BiS3 NDs at different time points. (B) The excretion proﬁles of Cu3BiS3 NDs in
mice at different time points. (C) Time-dependent copper species from degraded Cu3BiS3 NDs in deionized (DI) water. Reprinted with permission from
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metabolism mechanism of Cu3BiS3 NDs in a biological
environment is proposed as follows (Figure 3C). For Cu in
an acidic medium, mimicking the lysosomes, nine species
exist—Cu, CuS, Cu2S, CuCl2, CuCl, Cu2O, CuO, Cu (CH3
COO−)2, and Cu citrate (in forms of Cu+ and Cu2+)—
which are considered as the reference forms to ﬁnd the
chemical behavior of Cu3BiS3 NDs in an environment
mimicking the body. In the artiﬁcial lysosomal ﬂuid
(ALF), the Cu3BiS3 NDs are gradually converted into
a Cu-COO- species. In ALF, the NDs rapidly degrade
and form a Cu2S type with a level of 40% within a halfhour, while none was found after one day due to a quick
degradation process for Cu3BiS3 NDs. On the other hand,
CuCl served as a middle type between Cu2S and Cu-COO
species, given that no steady ratio for CuCl was found.
After one day, the level of CuS or CuCl2 species was
detected to be 2.5% and 6.7%, respectively, whereas the
Cu-COO level was 90.8% in an ALF solution. In contrast,
after 60 days in the DI water solution, the Cu3BiS3 NDs
were converted to Cu2S (20.6%), Cu-COO- (46.7%) and
CuS (12.6%), and a predictable CuO (20%) type was
oxidized in a non-acidic environment.
The novel (BiO)2CO3 nanoclusters (BNCs) assembled
into extended and hollow (BiO)2CO3 nanotubes (BNTs)
showing a high renal clearance efﬁciency in vivo during

a short time (Figure 4A).81 Importantly, the large size
BNTs (HD=98 nm) reconverted to the disassembled
small BNCs (core size of 1.5 nm) in a slightly acidic
medium, such as the tumor environment. The TEM images
of the incubated tumor cells showed a shortened length of
BNCs in cells, conﬁrming the degradation of the tubular
assembly (Figure 4B). The disassembled BNCs easily
passed renal ﬁltration and were cleared via the urinary
system (Figure 4C). Within 12h, the excreted Bi content
via the renal route was measured to be ~36%; interestingly, this amount was lower than 1% for the fecal route.

Pharmacokinetics (PK)
When foreign substances (either drug or contrast agent)
enter into the body, their interaction with each of the body
organs is a critical issue. The absorption, distribution, metabolism, and excretion (ADME) are four types of main
processes deﬁned as PK (Figure 5A). It should be noted
that the concentration of exogenous agents in systemic
blood circulation is mostly relevant to their accumulated
dose in the body. Consequently, to investigate the PK behavior of a probe, the measurement of its blood concentration
at different time points is necessary following the injection
of a dose, as long as the substance is removed in the body
(elimination phase). The main PK parameters—such as

A
Assembly
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Figure 4 (A) Mechanism of the pH-induced disassembly of hollow (BiO)2CO3 nanotubes (BNTs). (B) Transmission electron microscopy (TEM) images of BNTs dispersed in
a phosphate buffer saline (PBS) solution (pH 5.5) at different time points. (C) TEM images of BNTs in urine collected from a mouse after 3 h. Reprinted with permission from
Hu X, Sun J, Li F, et al. Renal-clearable hollow bismuth subcarbonate nanotubes for tumor targeted computed tomography imaging and chemoradiotherapy. Nano
Lett. 2018;18(2):1196–1204.81 Copyright 2018, American Chemical Society.
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maximum blood concentration (Cmax), elimination half-life
(t1/2) and area under the curve (AUC)—can be obtained
from the ﬁtted time-dependent concentration curve
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reveal tumor homing capability. To boost the enhanced
permeation and retention (EPR) effect and subsequently
improve tumor homing efﬁciency, high blood concentration,
long blood clearance half-life and large area under the curve
are desirable, due to the passage of nanoprobes from tumor
leaky vessels to a tumor extracellular environment as an
accumulative process.82–85
Based on the previous studies, the PK behavior of Bi
NPs has followed either one-compartment or twocompartment models. PEG molecules with an amphiphilic
nature are well-known as effective ligands to prolong
retention time in the blood; a clearance half-life of ~ 3–5
h was observed in PEGylated Bi NPs with different sizes.
An elimination half-life of 3.0, 3.97 and 3.83 h were
observed for Bi NCs (HD= 110 nm),4 Bi NPs (HD= 12
nm)32 and Bi NPs (HD= 45 nm)55 with PEG5000 coatings,
respectively. For PEG2000, the retention time of Gd-Bi NPs
in the blood extended to 4.69 h.58 For Bi2WO6-DOX-PEG
NPs (117 nm),11 the blood half-life circulating time was
calculated as 3.23 h. The constants of eliminating the rate
of Bi2WO6-DOX-PEG was calculated as −0.334 μg mL-1.
h-1 in the ﬁrst stage, then gradually decreased to −0.019
μg mL-1.h-1 in the second stage, also the time interval
changes were 2.34 h. The percentage of the volume of
Bi2WO6-DOX-PEG in the whole blood demonstrates signiﬁcant increasing distribution kinetics.
HSA also offered long-term circulation in the blood, as
the t1/2 of 3.8 h was measured for HSA- Bi2Se3@PDA
NPs (core size of 112 nm).54 Ultrasound nanocapsules,
such as poly (lactic-co-glycolic acid) (PLGA) and perﬂuorohexane (PFH) carrying Bi2S3, had very large hydrodynamic sizes (HD= 754.6 nm and 458.5 nm) and showed
a t1/2 of 9.44 min (~ 0–2 h p.i.) and 2.2h (~ 0–24 h p.i.),
respectively.86 The circulation times for PVP-Bi NPs were
almost the same with a half-life < 2 h, regardless of their
sizes. The t1/2 of PVP1000- Bi2Se3 SSNs (HD= 217 nm)
was ~1.7 h.3 In the case of PVP55000-Bi2Se3 nanoplates
(HD= 59.8 nm), the concentration of both Bi (t1/2= 1.9 h)
and Se (t1/2= 1.5 h) elements harshly degraded in the ﬁrst
phase, and then Se followed a declining manner with
a very low slope, while in contrast, the Bi element concentration was almost steadily up to 70 h.8 The probes
based on small molecules typically have a short distribution half-life (t1/2α<0.5 h) and elimination half-life (t1/2β),
followed by a two-compartment model for PK proﬁle and
a rapid renal elimination.76 The t1/2α and t1/2β of ultrasmall BSA-Bi2Se3 NDs (HD <10 nm) were 0.16 h and
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1.49 h, respectively (Figure 6A).26 Surprisingly, the distribution half-life of the BSA-Bi2S3 NPs (HD= 39.5 nm)28
extended to 14.85 h, which was as long as 10 times than
that of BSA-Bi2Se3 NDs, while their elimination half-life
was found to be 0.78 h.
In the case of (BiO)2CO3 BNCs embedded into long and
hollow (BiO)2CO3 nanotubes (BNTs),81 their PK proﬁle
followed a two-compartment model that incorporated the
beneﬁts of both small molecular probes and nanoprobes
(Figure 6B). These advantages include a short distribution
half-life (t1/2α = 27.6 min, like small molecular probes <30
min) and very long elimination half-life (t1/2α = 26.99 h)
which allowed nanoprobes to ﬂow in the blood at
a relatively high level, even 24 h after injection (~ 10%
ID•g−1), causing their continuous leakage from the blood
vessels into the tumor. The PK proﬁle of BNCs also followed a two-compartment pharmacokinetic model with
a t1/2α of 5.4 min and t1/2β of 3.77 h (about 7 times shorter
than that of the BNTs), during a period of ~ 0–24 h p.i..
PEG can be introduced as a superior choice to modify the surface of nanosystems concerning the following
capabilities improving hemo and-cytocompatibility,
reducing nonspeciﬁc protein adsorption and avoiding
opsonization. Thus, PEGylated NPs are retained in the
blood circulation for a prolonged time, due to the
“stealth” effect of PEG. Nevertheless, clotted blood
and anti-PEG immunoglobulin M antibody may occur
after the introduction of PEGylated NPs within the
body.87,88
For the active suppression of this immune attack, the
membrane of RBCs as a superior alternative has recently
gained attention, due to its countless numbers of glycans,
proteins and acidic sialyl moieties. Therefore, the RBC
membrane not only merits from biocompatibility, biodegradability, and non-immunogenicity but also the prolonged
circulatory residence time of RBC membrane-camouﬂaged
NPs. A superior blood circulation retention time was measured for the RBC membrane-modiﬁed Bi NPs53 in comparison to unmodiﬁed ones, indicating the major role of the
RBC membrane to decrease macrophage uptake, delay
clearance and prolong circulation time. In contrast, there
was no contribution to folate modiﬁcation—a similar blood
circulation period as the ones modiﬁed with RBC only was
found for folate functional RBC-membrane-modiﬁed Bi
NPs (F-RBC Bi NPs). The blood retention time of RBC
membrane-coated Bi NPs was considerably extended as
high as over 24 h, and their blood content was ~11%
ID•g−1 even at 24 h after injection, over 9-times larger
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Figure 6 (A) Blood circulation proﬁle of bovine serum albumin coated bismuth selenide nanoparticles (BSA-Bi2S3 NPs) in mice ﬁtted with a two-compartment model.
Reprinted with permission from Mao F, Wen L, Sun C, et al. Ultrasmall biocompatible Bi2Se3 nanodots for multimodal imaging-guided synergistic radiophotothermal therapy
against cancer. ACS Nano. 2016;10(12):11145–11155.26 Copyright 2016, American Chemical Society. (B) Blood circulation proﬁle of bismuth (Bi) concentration in the hollow
(BiO)2CO3 nanotubes (BNTs) and (BiO)2CO3 nanoclusters (BNCs) in mice ﬁtted with a two-compartment model. Reprinted with permission from Hu X, Sun J, Li F,
et al. Renal-clearable hollow bismuth subcarbonate nanotubes for tumor targeted computed tomography imaging and chemoradiotherapy. Nano Lett. 2018;18(2):1196–
1204.81 Copyright 2018, American Chemical Society.

than unmodiﬁed ones. These PK parameters of contrast
agents can quantitatively reﬂect the exposure of organs
and tissues to the agents and affect not only toxicity but
also tumor targeting efﬁciency.76

Conclusions and Prospects
Nanotechnology and nanomaterials are inevitable parts of
the modern, improved, and innovative scenarios in industrial and biomedical applications. Nanomaterials with their
unique, tailored, and size-dependent properties endow brilliant features to conventional materials. They can alter and
induce desired effects in very low quantities in comparison
to the bulk material; it is why they have attracted considerable attention. In this regard, it is critical to assess the
fate of nanomaterials within the human body and provide
suitable and speciﬁc guidelines toward their application
and handling. It is critical to evaluate exposure routes,
interactions with biological systems, pharmacokinetics,
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and clearance routes of nanostructures. Moreover, since
every type of nanostructure has its own mode of action,
the above-mentioned issues should be assessed for each
individual nanostructure.
Bi-based components have a long history in medicine
especially due to their antimicrobial activities. With the
advent of nanotechnology, considerable attention has been
paid to nanostructured bismuth, their properties, and applications. Various studies conducted along with this concept and
their pros and cons were documented in this unique review.
However, there has been a lack of a comprehensive review
evaluating their mode of action within the human body.
Various studies reported high biocompatibility and, interestingly, optimal biodegradability of BiNPs for medical applications. It is shown that dissolved Bi (III) ions from BiNPs
are cleared via metallothionine, a cysteine-rich protein in
kidneys, and excerted by urine. Bi-based nanocompounds
exhibited excellent blood compatibility with a hemolysis
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effect lower than 2%, even at a high concentration of 800
µg•mL−1. The physical states of the animal models were
monitored after the administration of BiNPs and the results
showed no signiﬁcant weight loss. Also, it has been reported
that no obvious abnormal behavior was observed after treatment, indicating physically and behaviorally excellent
in vivo compatibility of BiNPs. In addition to the physical
signs, histological evaluations conﬁrmed that BiNPs with
various shapes, coatings, and compounds did not induce
any signiﬁcant tissue damage and all major organs (heart,
liver, spleen, lung, and kidney) maintained normal physiological properties.
Since most of the prepared and evaluated BiNPs were
larger than FST, they followed a non-renal clearance proﬁle and demonstrated liver homing in the range of 8 ~ 70%
ID•g−1 at 1 ~ 24 h p.i. with any shape, hydrodynamic size
(larger than FST), surface coating and chemical composition. Even though various studies have been conducted to
assess the fate of BiNPs in the human body, protein corona
formation details have been neglected so far. Protein corona formation, its status, and dynamics are critical parameters determining the fate of NPs and the effectiveness of
the proposed medical application. According to the
authors’ opinion, it is essential to assess and control the
protein corona using simulation and experimental studies.
In conclusion, Bi-based nanostructures exhibited beneﬁcial
properties and can be considered as a promising diagnostic, therapeutic, and even theranostic agent.
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